Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Drug use affects chemotherapy completion in elderly ovarian cancer patients

12 May 2020

In elderly adults with ovarian cancer, potential drug interactions (PDIs) may interfere with chemotherapy completion, while polypharmacy (PP) and potentially inappropriate medications (PIMs) pose mortality risks, a recent study has shown.

Accessing the Danish Gynaecological Cancer Database, researchers identified 3,795 women (median age, 65 years) with epithelial ovarian cancer. Drug use was measured as the number of different drug substances purchased 4 months before diagnosis. This information was used to assess PP, PDIs and PIMs.

Of the participants, 2,219 had a registered date of surgery and underwent chemotherapy either with platinum monotherapy or in combination with a taxane. In multivariate Cox regression analysis, having at least two PDIs was the strongest predictor of not completing a minimum of six courses of chemotherapy (odds ratio, 2.27. 95 percent confidence interval [CI], 1.18–4.37).

Other risk factors included a Charlson Comorbidity Index score of 1–2, being on platinum monochemotherapy and performance status.

More than half (57.2 percent) of the patients had died by the study’s end, with 1,203 deaths attributable to cancer. The median survival was 45.3 months. Major (hazard ratio [HR], 3.15, 95 percent CI, 1.59–6.22) and extensive (HR, 5.43, 95 percent CI, 2.34–12.6) PP significantly raised mortality risk 0–6 months after diagnosis.

From 6–12 months after diagnosis, having 1–2 (HR, 1.50, 95 percent CI, 1.06–2.11) and 3 (HR, 2.38, 95 percent CI, 1.25–4.50) PIMs emerged as significant risk factors for death.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.